Redefining the Discovery and Design of Cancer Antibodies
Adagene is a private, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.
Platform Driven Precision Immunotherapy by Multiple Modalities
Disclosed Global Partnerships and Collaborations
Adagene has global partnerships and collaborations with four international organizations.
ADG106: CD137/4-1BB agonist
- Unique epitope with novel MOA
ADG116: Novel CTLA-4 antagonist
- Unique epitope for effective Treg depletion and soft CTLA-4 ligand blocking
ADG126: Lead SAFEbodyTM program targeting CTLA-4
- Designed to enhance the safety profile of a CTLA-4 targeting antibody
Dynamic Precision Antibody Technology Driving Rational Immunotherapies
- Targeting unique epitope with novel MOA
- Precision masking and local activation in TME
- Empowered efficacy with local activation in TME
Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class.
We have forged strategic partnerships with multiple reputable global companies. These partnerships leverage our technology in approaches at the vanguard of science, including safer precision-guided antibody-drug conjugates, transformative antibody design and advanced CAR constructs for significant unmet needs.
Founded and led by world-class leaders in antibody discovery and engineering, we have raised more than $150 million from high-profile investors. Adagene is well-positioned to address unmet needs in areas where other treatments have had little or no success.